AstraZeneca, european medicines agency and lung cancer
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU
AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision followed a feedback from the European Medicines Agency, the pharma company said Tuesday.
1don MSN
European markets were trading higher on Tuesday, in a shortened trading session for Christmas Eve. The pan-European Stoxx 600 ...
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy ...
Anavex (AVXL) stock rallied 30% Monday after the company announced EU regulators had accepted the market application for its ...
Life Sciences announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorization Application, ...
Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic ...
Hosted on MSN1d
Most European Bourses Track Higher Midday of Muted Tuesday Trading, Ahead of Holiday BreakMost European bourses were ahead midday Tuesday, though trading activities were muted as global markets are set to remain closed on Wednesday for the holiday. In corporate news, AstraZeneca (AZN) ...
Cytokinetics (CYTK) announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, MAA, for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback